Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.
Synopsis:
In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. discusses the company's shift from cardiovascular to oncology, highlighting their groundbreaking work in antibody-drug conjugates (ADCs) and HER2-targeted therapies. He shares his career journey and the importance of building a passionate, innovative team. Ken also emphasizes the role of strategic partnerships in accelerating drug development and ensuring global access to treatments. This conversation provides valuable insights into the future of cancer therapies and the biotech industry.
Biography:
Ken Keller is the Chairman of the Board President and Chief Executive Officer of Daiichi Sankyo, Inc. He is also the Head of the Global Oncology Business responsible for leading the overarching company strategy of ensuring innovative medicines are available to patients with cancer around the world. With more than 30 years of experience in the pharmaceutical industry, Ken has led multi-billion dollar businesses in both U.S. and Europe while working to unify cross-functional teams to create a global infrastructure – enabling the commercial success of Daiichi Sankyo oncology and specialty medicines.
Through leadership roles in multiple markets, across cultures and within different healthcare systems, Ken has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth. With more than 20 years of oncology experience, Ken had a longstanding career at Amgen where he held several leadership roles, with increasing global and commercial responsibility, including Vice President and General Manager, Bone Health Business Unit. Prior to joining Daiichi Sankyo, Ken served as Chief Operating Officer at Spectrum Pharmaceuticals, where he held global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations.
Ken is motivated by passion for innovation and compassion for patients, which is at the core of everything he instills within his leadership teams. Developing and coaching high-performing global teams that can have a profound impact on patient lives and leading an organization that is responsible for helping to change the standard of care for the oncology community is a privilege he is incredibly grateful for.